202 related articles for article (PubMed ID: 28778399)
1. Therapeutic Drug Monitoring in Inflammatory Bowel Disease: Clinical Decision Support Tool.
American Gastroenterological Association
Gastroenterology; 2017 Sep; 153(3):858-859. PubMed ID: 28778399
[No Abstract] [Full Text] [Related]
2. Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Patient Guide.
American Gastroenterological Association
Gastroenterology; 2017 Sep; 153(3):860-861. PubMed ID: 28774545
[No Abstract] [Full Text] [Related]
3. Usefulness of mean corpuscular volume as a surrogate marker for monitoring thiopurine treatment in inflammatory bowel disease.
Dujardin RW; Meijer B; de Boer NK; D'Haens GR; Löwenberg M
Eur J Gastroenterol Hepatol; 2016 Sep; 28(9):991-6. PubMed ID: 27257870
[TBL] [Abstract][Full Text] [Related]
4. Update on pathogenesis and predictors of response of therapeutic strategies used in inflammatory bowel disease.
Quetglas EG; Mujagic Z; Wigge S; Keszthelyi D; Wachten S; Masclee A; Reinisch W
World J Gastroenterol; 2015 Nov; 21(44):12519-43. PubMed ID: 26640330
[TBL] [Abstract][Full Text] [Related]
5. Inflammatory Bowel Disease: Pathophysiology and Current Therapeutic Approaches.
Abraham BP; Ahmed T; Ali T
Handb Exp Pharmacol; 2017; 239():115-146. PubMed ID: 28233184
[TBL] [Abstract][Full Text] [Related]
6. Which patients with inflammatory bowel disease should receive combination therapy?
Cross RK
Expert Rev Gastroenterol Hepatol; 2015 Jun; 9(6):715-7. PubMed ID: 25912620
[TBL] [Abstract][Full Text] [Related]
7. Guidelines for the management of inflammatory bowel disease in adults.
Carter MJ; Lobo AJ; Travis SP;
Gut; 2004 Sep; 53 Suppl 5(Suppl 5):V1-16. PubMed ID: 15306569
[No Abstract] [Full Text] [Related]
8. Clinical Decision Support Tools: The Evolution of a Revolution.
Mould DR; D'Haens G; Upton RN
Clin Pharmacol Ther; 2016 Apr; 99(4):405-18. PubMed ID: 26785109
[TBL] [Abstract][Full Text] [Related]
9. Adverse events of IBD therapies.
Scribano ML
Inflamm Bowel Dis; 2008 Oct; 14 Suppl 2():S210-1. PubMed ID: 18816669
[No Abstract] [Full Text] [Related]
10. Dalbavancin, tedizolid phosphate, oritavancin diphosphate, and vedolizumab.
Hussar DA; Nguyen A
J Am Pharm Assoc (2003); 2014; 54(6):658-62. PubMed ID: 25379985
[No Abstract] [Full Text] [Related]
11. On therapeutic drug monitoring of thiopurines in inflammatory bowel disease; pharmacology, pharmacogenomics, drug intolerance and clinical relevance.
Van Asseldonk DP; de Boer NK; Peters GJ; Veldkamp AI; Mulder CJ; Van Bodegraven AA
Curr Drug Metab; 2009 Nov; 10(9):981-97. PubMed ID: 20214590
[TBL] [Abstract][Full Text] [Related]
12. An update on biosimilar drugs for inflammatory bowel disease.
Schreiber S
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():1-3. PubMed ID: 26395529
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the drug treatment regimens for inflammatory bowel disease.
Brock EM; Zabihollah M
Expert Opin Pharmacother; 1999 Nov; 1(1):15-8. PubMed ID: 11249558
[No Abstract] [Full Text] [Related]
14. Safety of infliximab and other biologic agents in the inflammatory bowel diseases.
Reddy JG; Loftus EV
Gastroenterol Clin North Am; 2006 Dec; 35(4):837-55. PubMed ID: 17129816
[TBL] [Abstract][Full Text] [Related]
15. Thiopurines during pregnancy in inflammatory bowel disease: is there a risk for the (unborn) child?
de Boer NK; de Meij T; van Bodegraven AA
Expert Rev Gastroenterol Hepatol; 2013 Nov; 7(8):669-71. PubMed ID: 24134152
[No Abstract] [Full Text] [Related]
16. Managing Crohn's Disease After Surgery: A Patient Guide.
American Gastroenterological Association Institute
Gastroenterology; 2017 Jan; 152(1):296-297. PubMed ID: 27893980
[No Abstract] [Full Text] [Related]
17. Cardiovascular involvement in inflammatory bowel disease: Dangerous liaisons.
Filimon AM; Negreanu L; Doca M; Ciobanu A; Preda CM; Vinereanu D
World J Gastroenterol; 2015 Sep; 21(33):9688-92. PubMed ID: 26361415
[TBL] [Abstract][Full Text] [Related]
18. The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?
Ben-Horin S; Heap GA; Ahmad T; Kim H; Kwon T; Chowers Y
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():27-34. PubMed ID: 26395532
[TBL] [Abstract][Full Text] [Related]
19. Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases.
Danese S; Panés J
Gastroenterology; 2014 Nov; 147(5):981-9. PubMed ID: 25220794
[TBL] [Abstract][Full Text] [Related]
20. Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment.
Quetglas EG; Armuzzi A; Wigge S; Fiorino G; Barnscheid L; Froelich M; Danese S
Eur J Clin Pharmacol; 2015 Jul; 71(7):773-99. PubMed ID: 26008212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
